Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New GSK-Verily JV Aims For Smart, 'Grain Of Rice' Neuromod Tech

Executive Summary

Galvani Bioelectronics, the new joint venture between Google’s health-care spinoff Verily and drug giant GSK, will develop a new generation of "bioelectronic medicines" – neuromodulating therapies to treat a wide range of chronic diseases. Brian Otis, CTO of Verily, tells Medtech Insight how the devices that will come out of Galvani differ from existing neuromodulation technologies.

You may also be interested in...



Accenture Prescribes A New Data Management Future For Medtechs

The value of revenue streams derived from new business models is increasingly defined by how well companies manage the data within their ecosystems. Managing the data in the "last mile" subset provides an opportunity for medtech companies to generate income in that revenue stream, says Maximilian Schmid, head of the Global MedTech Practice at Accenture Life Sciences. 

Market Intel: Bioelectronics, Imaging Fortify Medtech's Defense Against Rheumatoid Arthritis

As rheumatoid arthritis treatment improves in the biologics era, patients need fewer joint replacements. Instead, they now require more closely monitored, agile care, in the face of a growing shortage of qualified rheumatologists. These demands help propel digital health applications, bioelectronic devices and novel imaging modalities into the medtech spotlight.

VC Deals Analysis: Liquid Biopsy Summons Yet Another Top A-Lister

While August may have broken the short summer bull run, last month's batch of venture fundraisings did have one redeeming feature – it recorded the biggest Series A round this year to date, a $50m deal by liquid biopsy company Karius.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT103665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel